Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data

The use of epidermal growth factor receptor (EGFR) inhibitors such as osimertinib has improved outcomes and quality of life for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Osimertinib has become the preferred EGFR tyrosine kinase inhibitor (TKIs) for patients with these mutations...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chung-Shien, Milone, Matthew, Seetharamu, Nagashree
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405228/
https://www.ncbi.nlm.nih.gov/pubmed/34471361
http://dx.doi.org/10.2147/OTT.S227032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405228/
https://www.ncbi.nlm.nih.gov/pubmed/34471361
http://dx.doi.org/10.2147/OTT.S227032

Ejemplares similares